Study title: A phase III, double-blind, parallel-group, randomized, comparative, two-centre study on gadodiamide injection (Omniscan) and Magnevist® at 0.1 mmol/kg b.w. in MR examinations of the CNS in children and adolescents in a 0.5 T Philips Gyroscan MR unit at the University Hospital Eppendorf, Hamburg, Germany, and in a 1.5T Philips Gyroscan S15 MR unit at the Department of Diagnostic Radiology, University of Cologne, Cologne, Germany
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Diagnosis | |||||
| Brands: Please see report, Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: GADODIAMIDE | |||||
| ATC code: | |||||
| Document link: SOV033 Redacted.pdf | |||||
| Document date: 2011-09-30 | |||||
| Study number: SOV033 | |||||
| EudraCT number: | |||||
| Scope of study: CLINICAL | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | - | - | |